These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16481168)

  • 21. Polysulfide reagent in solid-phase synthesis of phosphorothioate oligonucleotides: greater than 99.8% sulfurization efficiency.
    Krotz AH; Hang A; Gorman D; Scozzari AN
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(9):1293-9. PubMed ID: 16252666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of chimeric oligonucleotides containing phosphodiester, phosphorothioate, and phosphoramidate linkages.
    Maier MA; Guzaev AP; Manoharan M
    Org Lett; 2000 Jun; 2(13):1819-22. PubMed ID: 10891166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups.
    MacKellar C; Graham D; Will DW; Burgess S; Brown T
    Nucleic Acids Res; 1992 Jul; 20(13):3411-7. PubMed ID: 1630912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity.
    Ferrari N; Bergeron D; Tedeschi AL; Mangos MM; Paquet L; Renzi PM; Damha MJ
    Ann N Y Acad Sci; 2006 Oct; 1082():91-102. PubMed ID: 17145930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense oligonucleotides, aptamers and SiRNA: promises for the treatment of ocular diseases.
    Fattal E; Bochot A
    Arch Soc Esp Oftalmol; 2006 Jan; 81(1):3-4, 5-6. PubMed ID: 16450253
    [No Abstract]   [Full Text] [Related]  

  • 26. RNA targeted therapeutics for hematologic malignancies.
    Gewirtz AM
    Blood Cells Mol Dis; 2007; 38(2):117-9. PubMed ID: 17215146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A semi-empirical Hückel molecular orbital analysis of internucleotide phosphorothioate diesters.
    Weltman JK; Karim AS
    Anticancer Res; 1998; 18(4A):2733-6. PubMed ID: 9703937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in antisense therapeutics.
    Crooke ST
    Hematol Pathol; 1995; 9(2):59-72. PubMed ID: 7559256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation.
    Iversen PL
    Curr Opin Mol Ther; 2001 Jun; 3(3):235-8. PubMed ID: 11497346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligonucleotides make sensible strides.
    Doran G
    Drug Discov Today; 2004 Feb; 9(3):114-6. PubMed ID: 14960388
    [No Abstract]   [Full Text] [Related]  

  • 31. Solid-phase synthesis of siRNA oligonucleotides.
    Beaucage SL
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):203-16. PubMed ID: 18283608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RNA-based therapeutics--from design to the clinic.
    Iversen P
    Curr Opin Mol Ther; 2009 Apr; 11(2):107. PubMed ID: 19330715
    [No Abstract]   [Full Text] [Related]  

  • 33. Crohn's trial shows the pros of antisense.
    Robertson D
    Nat Biotechnol; 1997 Mar; 15(3):209. PubMed ID: 9062911
    [No Abstract]   [Full Text] [Related]  

  • 34. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and properties of photo-reactive antisense oligonucleotides containing 2'-O-psoralen-conjugated adenosine.
    Higuchi M; Yamayoshi A; Kobori A; Yamaoka T; Murakami A
    Nucleic Acids Symp Ser (Oxf); 2005; (49):331-2. PubMed ID: 17150768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense phosphorothioate oligodeoxyribonucleotide targeted against ICAM-1: synthetic and biological characterization of a process-related impurity formed during oligonucleotide synthesis.
    Ravikumar VT; Capaldi DC; Lima WF; Lesnik E; Turney B; Cole DL
    Bioorg Med Chem; 2003 Oct; 11(21):4673-9. PubMed ID: 14527564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of antisense oligonucleotide and siRNA-based therapeutics.
    Chi X; Gatti P; Papoian T
    Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dimethylthiarum disulfide: new sulfur transfer reagent in phosphorothioates oligonucleotide synthesis.
    Wang Z; Song Q; Sanghvi YS
    Methods Mol Biol; 2005; 288():51-64. PubMed ID: 15333897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Oligonucleotide therapeutics - an emerging novel class of compounds].
    Wacheck V
    Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and in vitro characterization of an ABC triblock copolymer for siRNA delivery.
    Segura T; Hubbell JA
    Bioconjug Chem; 2007; 18(3):736-45. PubMed ID: 17358044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.